{"success":true,"data":{"pressRelease":{"id":"114075","rtpr_id":"nGNX8Jghzk","ticker":"ARTL","exchange":"NASDAQ","all_tickers":["ARTL"],"title":"Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma","author":"Globe Newswire","published_at":"2026-08-10T12:47:00.033Z","article_body":"Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands\nART27.13’s clinical potential into ophthalmology\n\nInitial DREAM Study Results Anticipated in Q4 2026\n\nSOLANA BEACH, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences,\nInc.\n(https://www.globenewswire.com/Tracker?data=3-nE1NubxB_LqKdPRnf3OpBKvm68-lNr6S4y7mFTeTrfIz3cD9SZo-VO_YJ7opkfeqK6WxfH90SxjXqXDv64C89Plpp3mbhqhNe9S3YF1QNNjMrNv1UP09vffb7Xln-f8_l_Tx4krdpIQ8-_3vjd2GDLO2wfEb8Z9UatPcGvpJPziCyOVAjEOMnjl4kxr-pJASWhMbQh2IOvafLrxQR3J6ubXHY1uHJkx2E0FjxdZu3RwFqcXBfFT_8SSNKkw5CTTKfXEyBvrthmgHrkUIMMNQ==) (Nasdaq: ARTL), a\nclinical-stage pharmaceutical company focused on modulating lipid-signalling\npathways to develop treatments for people living with cancer, pain,\ndermatologic, or neurological conditions, today announced the first patient\nhas been dosed in the DREAM study (Determining the Role of synthetic\ncannabinoids in Eye pressure And tolerability Measurements), which will\nevaluate the effects of Artelo’s orally administered synthetic cannabinoid,\nART27.13, in patients with glaucoma or ocular hypertension.\n\nART27.13, a peripherally selective synthetic cannabinoid receptor agonist,\nrepresents a novel therapeutic approach aimed at modulating intraocular\npressure (IOP) through activation of cannabinoid receptors located in ocular\ntissues.\n\nFunding for the DREAM study is being provided by Glaucoma UK and the HSC R&D\nDivision\n(https://www.globenewswire.com/Tracker?data=uMinBpmETzk4PEtx0ff846Uy2QoTQ8Ogc3WtzotUh-VNplWSf_pf-RPlWrboKzpoNf-tLbgMUP42Gh6ovwWhjsu7ETKDJ1KAzeIC9RBMDTWdnf0n2Esugms_7-oJ1J3Xeo1wWykbmRUfGoMd8V5RYqmNLbAGy9c30zI9aEZ3sXcY0eTR6ah2OzRM5VkwfgjedwnrSPZCVJ7l4i5vtQP62-G4K7gz4f0fF7nQWILMVH1tPldKsZiyP0704ZQjq4-Ia3ADIUxpf5CxtLxEvKxZOQ==).\nThe study is sponsored by the Belfast Health and Social Care Trust and is\nbeing conducted by the Northern Ireland Clinical Trials Unit. Clinical\nProfessor of Ophthalmology at Queen’s University Belfast and Honorary\nConsultant Ophthalmologist at Belfast Health and Social Care Trust, Professor\nAugusto Azuara-Blanco, a globally recognized authority in glaucoma management\nand clinical research, is leading the DREAM study.\n\n“There remains an urgent need for safe, well-tolerated, and effective new\ntreatments for glaucoma that can provide additional options to reduce\nintraocular pressure and preserve vision,” said Professor Azuara-Blanco.\n“The potential role of peripherally selective cannabinoids in ocular health\nis an exciting and largely unexplored area. This study is expected to provide\nimportant insights into whether ART27.13, which is designed to act outside the\ncentral nervous system, can safely lower intraocular pressure without\npsychotropic side effects.”\n\nGlaucoma is a leading cause of irreversible blindness, affecting more than 80\nmillion people worldwide. Elevated IOP is the primary modifiable risk factor\nfor glaucoma progression, but existing therapies—mostly topical eye\ndrops—often face limitations related to adherence, local tolerability, and\nlong-term efficacy.\n\n“We are excited to announce this fully funded Phase 2 clinical study,\nevaluating ART27.13 in glaucoma, has enrolled its first patient,” said\nGregory D. Gorgas, President and Chief Executive Officer of Artelo\nBiosciences. “The DREAM study has the potential to demonstrate whether an\norally active cannabinoid has a role in managing intraocular pressure.\nART27.13’s peripherally selective design may overcome the challenges of CNS\nadverse effects which has been an issue when other oral or topical\ncannabinoids have been explored in this indication. We are looking forward to\nannouncing initial results from the DREAM study later this year.”\n\nAbout ART27.13\nART27.13 is a novel benzimidazole derivative and dual cannabinoid agonist.\nInitially developed by AstraZeneca plc, ART27.13 has been in seven clinical\nstudies with over 280 participants. It is being developed as a once-daily,\norally administered agent selectively targeting peripheral CB(1) and\nCB(2) receptors, with the potential to reduce muscle degeneration while\nimproving body weight, appetite, and quality of life in cancer patients. A\nstatistically significant and dose-dependent increase in body weight was\nobserved in people with back pain who were otherwise healthy. Importantly, the\ndrug enables systemic metabolic effects while minimizing central nervous\nsystem-mediated toxicity. Artelo is conducting a Phase 2 named the Cancer\nAppetite Recovery Study (CAReS) evaluating ART27.13 as a supportive care\ntherapy for cancer patients suffering from anorexia and weight loss. Interim\nPhase 2 data revealed patients who had lost at least 5% of body weight to be\nincluded in CAReS and titrated to the highest ART27.13 dose (1300 µg)\nachieved an average +6% weight gain over 12 weeks, while patients on placebo\nlost an additional ~5%. Currently, there is no FDA approved treatment for\ncancer anorexia cachexia syndrome. In addition to CAReS, ART27.13 is also\nbeing evaluated in a Phase 2 study in people with glaucoma at a daily dose of\n650 µg.\n\nAbout Artelo Biosciences\nArtelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated\nto the development and commercialization of proprietary therapeutics that\nmodulate lipid-signaling pathways, with a diversified pipeline addressing\nsignificant unmet needs in anorexia, cancer, anxiety, dermatologic conditions,\npain, and inflammation. Led by an experienced executive team collaborating\nwith world-class researchers and technology partners, Artelo applies rigorous\nscientific, regulatory, commercial, and treasury management practices,\nincluding digital assets, to maximize stakeholder value. More information is\navailable at www.artelobio.com and X: @ArteloBio.\n\nForward-Looking Statements\nThis press release contains certain forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934 and Private Securities Litigation Reform Act,\nas amended, including those relating to the Company’s product development,\nclinical and regulatory timelines, market opportunity, competitive position,\npossible or assumed future results of operations, business strategies,\npotential growth opportunities and other statements that are predictive in\nnature. These forward-looking statements are based on current expectations,\nestimates, forecasts and projections about the industry and markets in which\nwe operate and management’s current beliefs and assumptions. These\nstatements may be identified by the use of forward-looking expressions,\nincluding, but not limited to, “expect,” “anticipate,” “intend,”\n“plan,” “believe,” “estimate,” “potential,” “predict,”\n“project,” “should,” “would” and similar expressions and the\nnegatives of those terms. These statements relate to future events or our\nfinancial performance and involve known and unknown risks, uncertainties, and\nother factors which may cause actual results, performance or achievements to\nbe materially different from any future results, performance or achievements\nexpressed or implied by the forward-looking statements. Such factors include\nthose set forth in the Company’s filings with the Securities and Exchange\nCommission, including our ability to raise additional capital in the future.\nProspective investors are cautioned not to place undue reliance on such\nforward-looking statements, which speak only as of the date of this press\nrelease. The Company undertakes no obligation to publicly update any\nforward-looking statement, whether as a result of new information, future\nevents or otherwise, except to the extent required by applicable securities\nlaws.\n\nInvestor Relations Contact:\nCrescendo Communications, LLC\nTel: 212-671-1020\nEmail: ARTL@crescendo-ir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/460502d7-b0d3-43d8-a15a-5b2bb963bbbb)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8Jghzk","title":"Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma","author":"Globe Newswire","ticker":"ARTL","created":"2026-08-10T12:47:00.033Z","tickers":["ARTL"],"exchange":"NASDAQ","article_body":"Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands\nART27.13’s clinical potential into ophthalmology\n\nInitial DREAM Study Results Anticipated in Q4 2026\n\nSOLANA BEACH, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences,\nInc.\n(https://www.globenewswire.com/Tracker?data=3-nE1NubxB_LqKdPRnf3OpBKvm68-lNr6S4y7mFTeTrfIz3cD9SZo-VO_YJ7opkfeqK6WxfH90SxjXqXDv64C89Plpp3mbhqhNe9S3YF1QNNjMrNv1UP09vffb7Xln-f8_l_Tx4krdpIQ8-_3vjd2GDLO2wfEb8Z9UatPcGvpJPziCyOVAjEOMnjl4kxr-pJASWhMbQh2IOvafLrxQR3J6ubXHY1uHJkx2E0FjxdZu3RwFqcXBfFT_8SSNKkw5CTTKfXEyBvrthmgHrkUIMMNQ==) (Nasdaq: ARTL), a\nclinical-stage pharmaceutical company focused on modulating lipid-signalling\npathways to develop treatments for people living with cancer, pain,\ndermatologic, or neurological conditions, today announced the first patient\nhas been dosed in the DREAM study (Determining the Role of synthetic\ncannabinoids in Eye pressure And tolerability Measurements), which will\nevaluate the effects of Artelo’s orally administered synthetic cannabinoid,\nART27.13, in patients with glaucoma or ocular hypertension.\n\nART27.13, a peripherally selective synthetic cannabinoid receptor agonist,\nrepresents a novel therapeutic approach aimed at modulating intraocular\npressure (IOP) through activation of cannabinoid receptors located in ocular\ntissues.\n\nFunding for the DREAM study is being provided by Glaucoma UK and the HSC R&D\nDivision\n(https://www.globenewswire.com/Tracker?data=uMinBpmETzk4PEtx0ff846Uy2QoTQ8Ogc3WtzotUh-VNplWSf_pf-RPlWrboKzpoNf-tLbgMUP42Gh6ovwWhjsu7ETKDJ1KAzeIC9RBMDTWdnf0n2Esugms_7-oJ1J3Xeo1wWykbmRUfGoMd8V5RYqmNLbAGy9c30zI9aEZ3sXcY0eTR6ah2OzRM5VkwfgjedwnrSPZCVJ7l4i5vtQP62-G4K7gz4f0fF7nQWILMVH1tPldKsZiyP0704ZQjq4-Ia3ADIUxpf5CxtLxEvKxZOQ==).\nThe study is sponsored by the Belfast Health and Social Care Trust and is\nbeing conducted by the Northern Ireland Clinical Trials Unit. Clinical\nProfessor of Ophthalmology at Queen’s University Belfast and Honorary\nConsultant Ophthalmologist at Belfast Health and Social Care Trust, Professor\nAugusto Azuara-Blanco, a globally recognized authority in glaucoma management\nand clinical research, is leading the DREAM study.\n\n“There remains an urgent need for safe, well-tolerated, and effective new\ntreatments for glaucoma that can provide additional options to reduce\nintraocular pressure and preserve vision,” said Professor Azuara-Blanco.\n“The potential role of peripherally selective cannabinoids in ocular health\nis an exciting and largely unexplored area. This study is expected to provide\nimportant insights into whether ART27.13, which is designed to act outside the\ncentral nervous system, can safely lower intraocular pressure without\npsychotropic side effects.”\n\nGlaucoma is a leading cause of irreversible blindness, affecting more than 80\nmillion people worldwide. Elevated IOP is the primary modifiable risk factor\nfor glaucoma progression, but existing therapies—mostly topical eye\ndrops—often face limitations related to adherence, local tolerability, and\nlong-term efficacy.\n\n“We are excited to announce this fully funded Phase 2 clinical study,\nevaluating ART27.13 in glaucoma, has enrolled its first patient,” said\nGregory D. Gorgas, President and Chief Executive Officer of Artelo\nBiosciences. “The DREAM study has the potential to demonstrate whether an\norally active cannabinoid has a role in managing intraocular pressure.\nART27.13’s peripherally selective design may overcome the challenges of CNS\nadverse effects which has been an issue when other oral or topical\ncannabinoids have been explored in this indication. We are looking forward to\nannouncing initial results from the DREAM study later this year.”\n\nAbout ART27.13\nART27.13 is a novel benzimidazole derivative and dual cannabinoid agonist.\nInitially developed by AstraZeneca plc, ART27.13 has been in seven clinical\nstudies with over 280 participants. It is being developed as a once-daily,\norally administered agent selectively targeting peripheral CB(1) and\nCB(2) receptors, with the potential to reduce muscle degeneration while\nimproving body weight, appetite, and quality of life in cancer patients. A\nstatistically significant and dose-dependent increase in body weight was\nobserved in people with back pain who were otherwise healthy. Importantly, the\ndrug enables systemic metabolic effects while minimizing central nervous\nsystem-mediated toxicity. Artelo is conducting a Phase 2 named the Cancer\nAppetite Recovery Study (CAReS) evaluating ART27.13 as a supportive care\ntherapy for cancer patients suffering from anorexia and weight loss. Interim\nPhase 2 data revealed patients who had lost at least 5% of body weight to be\nincluded in CAReS and titrated to the highest ART27.13 dose (1300 µg)\nachieved an average +6% weight gain over 12 weeks, while patients on placebo\nlost an additional ~5%. Currently, there is no FDA approved treatment for\ncancer anorexia cachexia syndrome. In addition to CAReS, ART27.13 is also\nbeing evaluated in a Phase 2 study in people with glaucoma at a daily dose of\n650 µg.\n\nAbout Artelo Biosciences\nArtelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated\nto the development and commercialization of proprietary therapeutics that\nmodulate lipid-signaling pathways, with a diversified pipeline addressing\nsignificant unmet needs in anorexia, cancer, anxiety, dermatologic conditions,\npain, and inflammation. Led by an experienced executive team collaborating\nwith world-class researchers and technology partners, Artelo applies rigorous\nscientific, regulatory, commercial, and treasury management practices,\nincluding digital assets, to maximize stakeholder value. More information is\navailable at www.artelobio.com and X: @ArteloBio.\n\nForward-Looking Statements\nThis press release contains certain forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934 and Private Securities Litigation Reform Act,\nas amended, including those relating to the Company’s product development,\nclinical and regulatory timelines, market opportunity, competitive position,\npossible or assumed future results of operations, business strategies,\npotential growth opportunities and other statements that are predictive in\nnature. These forward-looking statements are based on current expectations,\nestimates, forecasts and projections about the industry and markets in which\nwe operate and management’s current beliefs and assumptions. These\nstatements may be identified by the use of forward-looking expressions,\nincluding, but not limited to, “expect,” “anticipate,” “intend,”\n“plan,” “believe,” “estimate,” “potential,” “predict,”\n“project,” “should,” “would” and similar expressions and the\nnegatives of those terms. These statements relate to future events or our\nfinancial performance and involve known and unknown risks, uncertainties, and\nother factors which may cause actual results, performance or achievements to\nbe materially different from any future results, performance or achievements\nexpressed or implied by the forward-looking statements. Such factors include\nthose set forth in the Company’s filings with the Securities and Exchange\nCommission, including our ability to raise additional capital in the future.\nProspective investors are cautioned not to place undue reliance on such\nforward-looking statements, which speak only as of the date of this press\nrelease. The Company undertakes no obligation to publicly update any\nforward-looking statement, whether as a result of new information, future\nevents or otherwise, except to the extent required by applicable securities\nlaws.\n\nInvestor Relations Contact:\nCrescendo Communications, LLC\nTel: 212-671-1020\nEmail: ARTL@crescendo-ir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/460502d7-b0d3-43d8-a15a-5b2bb963bbbb)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-10T12:47:00.088915991Z","server_sent_at_ms":1786366020088},"received_at":"2026-08-10T12:47:00.143Z","source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341844/0/en/artelo-announces-enrollment-of-first-patient-in-a-phase-2-clinical-trial-evaluating-art27-13-for-treatment-of-glaucoma.html"},"analysis":{"id":"103076","press_release_id":"114075","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Artelo announced the first patient has been dosed in the Phase 2 DREAM study evaluating ART27.13 for the treatment of glaucoma or ocular hypertension.\n\nThe investigator-led study is fully funded by Glaucoma UK and the HSC R&D Division, sponsored by the Belfast Health and Social Care Trust, and led by Professor Augusto Azuara-Blanco.\n\nInitial results from the DREAM study are anticipated in Q4 2026, while a separate Phase 2 CAReS study continues to evaluate ART27.13 for cancer anorexia.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Phase 2 start for ART27.13 in glaucoma; externally funded study limits cash burn."},"keyFigures":{"drugName":"ART27.13","phaseOfTrial":"Phase 2","customDimensions":{"glaucoma_daily_dose":"650 µg","cares_placebo_weight_loss":"~5%","cancer_anorexia_daily_dose":"1300 µg","cares_weight_gain_high_dose":"+6%","previous_study_participants":"over 280"}},"quotedText":"We are excited to announce this fully funded Phase 2 clinical study, evaluating ART27.13 in glaucoma, has enrolled its first patient","namedEntities":{"people":[{"name":"Gregory D. Gorgas","role":"President and Chief Executive Officer"},{"name":"Professor Augusto Azuara-Blanco","role":"Principal Investigator"}],"products":["ART27.13"],"companies":[{"name":"Artelo Biosciences, Inc.","ticker":"ARTL"},{"name":"Glaucoma UK","relationship":"funder"},{"name":"HSC R&D Division","relationship":"funder"},{"name":"Belfast Health and Social Care Trust","relationship":"sponsor"},{"name":"AstraZeneca plc","ticker":"AZN","relationship":"originator"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"First patient dosed in Phase 2 DREAM study for lead asset ART27.13 in a new indication (glaucoma). While a positive operational milestone, the study is investigator-led and externally funded, which mitigates financial execution risk but is less definitive regarding commercial value than a pivotal company-sponsored trial."},"tickerRelevance":{"others":[{"ticker":"AZN","relevance":"originator"}],"primary":"ARTL"},"globalImportance":18,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"funding":"externally_funded","tickerTier":"micro-cap","eventGravity":"phase_2_initiation"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Artelo announced the first patient has been dosed in the Phase 2 DREAM study evaluating ART27.13 for the treatment of glaucoma or ocular hypertension.\n\nThe investigator-led study is fully funded by Glaucoma UK and the HSC R&D Division, sponsored by the Belfast Health and Social Care Trust, and led by Professor Augusto Azuara-Blanco.\n\nInitial results from the DREAM study are anticipated in Q4 2026, while a separate Phase 2 CAReS study continues to evaluate ART27.13 for cancer anorexia.","key_figures":{"drugName":"ART27.13","phaseOfTrial":"Phase 2","customDimensions":{"glaucoma_daily_dose":"650 µg","cares_placebo_weight_loss":"~5%","cancer_anorexia_daily_dose":"1300 µg","cares_weight_gain_high_dose":"+6%","previous_study_participants":"over 280"}},"named_entities":{"people":[{"name":"Gregory D. Gorgas","role":"President and Chief Executive Officer"},{"name":"Professor Augusto Azuara-Blanco","role":"Principal Investigator"}],"products":["ART27.13"],"companies":[{"name":"Artelo Biosciences, Inc.","ticker":"ARTL"},{"name":"Glaucoma UK","relationship":"funder"},{"name":"HSC R&D Division","relationship":"funder"},{"name":"Belfast Health and Social Care Trust","relationship":"sponsor"},{"name":"AstraZeneca plc","ticker":"AZN","relationship":"originator"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-10T17:24:13.038Z","global_importance":18,"audience_relevance":10,"importance_components":{"funding":"externally_funded","tickerTier":"micro-cap","eventGravity":"phase_2_initiation"}},"durationMs":264795,"modelName":"glm-4.7"}}